Direkt zum Inhalt
Merck
  • The stem cell potential and multipotency of human adipose tissue-derived stem cells vary by cell donor and are different from those of other types of stem cells.

The stem cell potential and multipotency of human adipose tissue-derived stem cells vary by cell donor and are different from those of other types of stem cells.

Cells, tissues, organs (2015-04-01)
Hyun Jin Yang, Ki-Joo Kim, Min Kyoung Kim, Su Jin Lee, Yeon Hee Ryu, Bommie F Seo, Deuk-Young Oh, Sang-Tae Ahn, Hee Young Lee, Jong Won Rhie
ZUSAMMENFASSUNG

Human adipose tissue-derived mesenchymal stem cells (AT-MSCs) from various sites are applied in tissue engineering and cell therapy. The condition of AT-MSCs depends on the donor's age, body mass index (BMI), and gender. AT-MSCs from 66 human donors were analyzed, and the cells were sorted according to donor age (10-19 years: n = 1; 20-29 years: n = 5; 30-39 years: n = 12; 40-49 years: n = 22; 50-59 years: n = 12; 60-69 years: n = 9, and 70 years or older: n = 5), BMI (under 25, 25-30, and over 30), and gender (19 males and 48 females). Additionally, AT-MSCs were compared to bone marrow MSCs and chorionic tissue-derived MSCs. We measured the MSC yield, growth rate, colony-forming units, multipotency, and surface antigens. AT-MSC proliferation was greater in cells isolated from individuals aged less than 30 years compared to the proliferation of AT-MSCs from those over 50 years old. BMI was correlated with osteogenic differentiation potency; increased BMI enhanced osteogenesis. Adipogenic differentiation was more strongly induced in cells isolated from donors aged less than 30 years compared to those isolated from other age groups. Also, a BMI above 30 was associated with enhanced adipogenic differentiation compared to cells isolated from individuals with a BMI below 25. Bone marrow MSCs were strongly induced to differentiate along both osteogenic and adipogenic lineages, whereas AT-MSCs predominantly differentiated into the chondrogenic lineage. Therefore, the type of regeneration required and variations among potential donors must be carefully considered when selecting MSCs for use in applied tissue engineering or cell therapy.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Guanidin -hydrochlorid, Molecular Biology, ≥99%
Sigma-Aldrich
Dexamethason, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
Guanidin -hydrochlorid, ≥99% (titration), organic base and chaeotropic agent
Sigma-Aldrich
Guanidin -hydrochlorid, ≥98%
Sigma-Aldrich
Dexamethason, ≥98% (HPLC), powder
Sigma-Aldrich
Guanidin -hydrochlorid -Lösung, BioUltra, ~8 M in H2O
Sigma-Aldrich
Guanidin -hydrochlorid -Lösung, Colorless liquid, 7.8 - 8.3 M, pH- 4.5 - 5.5
Supelco
Dexamethason, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Guanidin -hydrochlorid, ≥99.0% (AT)
Sigma-Aldrich
Cetylpyridiniumchlorid, meets USP testing specifications
Sigma-Aldrich
Dexamethason, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
USP
Dexamethason, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Guanidin -hydrochlorid, BioUltra, Molecular Biology, ≥99.5% (AT)
Sigma-Aldrich
Guanidin -hydrochlorid, anhydrous, free-flowing, Redi-Dri, ≥99%
Sigma-Aldrich
Dexamethason, meets USP testing specifications
USP
Cetylpyridiniumchlorid, United States Pharmacopeia (USP) Reference Standard
Cetylpyridiniumchlorid, European Pharmacopoeia (EP) Reference Standard
Dexamethason, European Pharmacopoeia (EP) Reference Standard
Supelco
Dexamethason, VETRANAL®, analytical standard
Sigma-Aldrich
Dexamethason, tested according to Ph. Eur.
Dexamethason, British Pharmacopoeia (BP) Assay Standard
Dexamethason für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard
Dexamethason für die Systemeignung, European Pharmacopoeia (EP) Reference Standard